Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
PTCT

PTCT - PTC Therapeutics Inc Stock Price, Fair Value and News

33.07USD-0.96 (-2.82%)Delayed

Market Summary

PTCT
USD33.07-0.96
Delayed
-2.82%

PTCT Alerts

  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

PTCT Stock Price

View Fullscreen

PTCT RSI Chart

PTCT Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-4.38

Price/Sales (Trailing)

2.73

EV/EBITDA

-6.15

Price/Free Cashflow

-29.52

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-69.63%

Return on Equity

64.8%

Return on Assets

-32.37%

Free Cashflow Yield

-3.39%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

927.6M

Rev. Growth (Yr)

-4.66%

Rev. Growth (Qtr)

-31.57%

PTCT Earnings

Earnings (TTM)

-579.2M

Earnings Growth (Yr)

34.1%

Earnings Growth (Qtr)

41.22%

Breaking Down PTCT Revenue

Last 7 days

2.5%

Last 30 days

31.4%

Last 90 days

27.6%

Trailing 12 Months

-43.1%

How does PTCT drawdown profile look like?

PTCT Financial Health

Current Ratio

2.03

Debt/Equity

-0.32

Debt/Cashflow

-0.2

PTCT Investor Care

Shares Dilution (1Y)

3.38%

Diluted EPS (TTM)

-7.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024927.6M000
2023770.4M818.7M798.2M937.8M
2022569.4M618.2M696.6M698.8M
2021430.4M471.9M492.2M538.6M
2020321.7M311.4M358.4M380.8M
2019261.8M278.5M296.4M307.0M
2018203.7M224.5M236.3M264.2M
201790.3M122.5M141.3M174.1M
201648.2M57.0M70.2M82.7M
201523.5M28.6M36.7M36.8M
201436.8M31.6M17.0M25.2M
201328.6M27.8M36.9M34.7M
2012113.1M115.9M36.7M33.9M
2011000105.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of PTC Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 08, 2024
southwell david p
gifted
-
-
-1,650
-
May 07, 2024
golden lee scott
sold
-5,743
32.82
-175
evp & chief medical officer
Apr 19, 2024
klein matthew b.
sold
-83,668
24.894
-3,361
chief executive officer
Apr 17, 2024
pauwels eric
sold
-19,781
25.135
-787
chief executive officer
Apr 17, 2024
klein matthew b.
sold
-32,851
25.135
-1,307
chief executive officer
Apr 02, 2024
golden lee scott
sold
-14,922
28.37
-526
evp & chief medical officer
Feb 15, 2024
okey stephanie
acquired
-
-
4,000
-
Feb 15, 2024
gravier pierre
acquired
-
-
22,100
chief financial officer
Feb 15, 2024
schmertzler michael
acquired
-
-
8,000
-
Feb 15, 2024
southwell david p
acquired
-
-
4,000
-

1–10 of 50

Which funds bought or sold PTCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.47
-4,368
1,987,810
-%
May 16, 2024
COMERICA BANK
unchanged
-
32.00
611
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-88.42
-19,785,700
2,754,500
-%
May 15, 2024
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)
reduced
-58.39
-557,243
436,350
0.03%
May 15, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
added
42.34
12,354,200
36,944,300
0.07%
May 15, 2024
VOLORIDGE INVESTMENT MANAGEMENT, LLC
reduced
-7.36
-501,807
22,090,400
0.08%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
reduced
-41.39
-302,944
491,417
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-72.13
-9,932,260
4,139,220
-%
May 15, 2024
JANUS HENDERSON GROUP PLC
added
40.47
34,740,100
106,744,000
0.06%
May 15, 2024
ALGERT GLOBAL LLC
sold off
-100
-992,000
-
-%

1–10 of 37

Are Funds Buying or Selling PTCT?

Are funds buying PTCT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PTCT
No. of Funds

Unveiling PTC Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.10%
6,864,000
SC 13G
Feb 14, 2024
rtw investments, lp
9.8%
7,423,970
SC 13G/A
Feb 13, 2024
vanguard group inc
11.66%
8,800,843
SC 13G/A
Feb 08, 2024
wellington management group llp
13.01%
9,816,603
SC 13G/A
Jan 24, 2024
state street corp
6.14%
4,633,955
SC 13G/A
Jan 10, 2024
fmr llc
-
0
SC 13G/A
Jan 08, 2024
blackrock inc.
10.2%
7,668,871
SC 13G/A
Nov 13, 2023
fmr llc
-
0
SC 13G/A
Oct 30, 2023
camber capital management lp
5.31%
2,013
SC 13G
Feb 14, 2023
rtw investments, lp
7.7%
5,615,387
SC 13G/A

Recent SEC filings of PTC Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 10, 2024
4
Insider Trading
May 08, 2024
4
Insider Trading
May 07, 2024
144
Notice of Insider Sale Intent
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A
Apr 25, 2024
10-Q
Quarterly Report
Apr 25, 2024
8-K
Current Report
Apr 22, 2024
4
Insider Trading
Apr 19, 2024
144
Notice of Insider Sale Intent
Apr 19, 2024
4
Insider Trading

Peers (Alternatives to PTC Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.57
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

PTC Therapeutics Inc News

Latest updates
Defense World26 hours ago
Yahoo Canada Shine On14 May 202401:10 pm

PTC Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-31.6%210,118,000307,056,000196,576,000213,808,000220,382,000167,412,500217,127,000165,526,000148,735,000165,230,500138,743,000116,676,000117,942,000118,864,000118,404,00075,239,00068,259,00096,459,00071,416,00085,522,00053,583,000
Operating Expenses-15.2%255,571,000301,236,000314,740,000423,351,000337,997,000367,752,000285,314,000257,888,000235,257,000249,958,500231,819,000215,169,000216,090,000215,238,000173,535,000262,512,000161,250,000169,243,000131,891,000124,280,000122,723,000
  S&GA Expenses-4.0%73,272,00076,291,00080,886,00088,449,00086,914,00092,717,50080,118,00079,892,00073,271,00086,548,00069,252,00068,878,00061,095,00075,456,00057,840,00053,659,00058,209,00063,497,50049,284,00049,215,00040,544,000
  R&D Expenses-4.3%116,129,000121,353,000164,212,000185,874,000195,124,000188,693,500165,462,000157,263,000140,078,000149,844,000130,845,000125,482,000134,513,000118,013,00092,998,000176,525,00090,107,00081,831,00063,076,00059,979,00052,566,000
EBITDA Margin11.7%-0.40-0.45-0.62-0.60-0.56-0.63-0.60-0.71-0.75-0.83-0.76-0.62---------
Interest Expenses73.7%3,666,0002,111,00011,710,0009,354,00012,956,0005,784,0004,406,0002,143,0006,130,000-1,0004,407,000-5,182,000-4,516,000408,0004,878,000651,0003,931,000-3,111,000
Income Taxes646.5%6,880,000-1,259,000-33,620,000-38,596,0003,969,000-18,804,000-17,893,0003,392,0004,835,0004,657,500-36,000488,000451,00012,634,00022,288,00084,000222,00010,644,000-344,000774,000576,000
Earnings Before Taxes46.1%-84,696,000-157,051,000-166,590,000-237,479,000-134,990,000-189,693,000-127,208,000-148,695,000-121,891,000-138,607,500-133,660,000-117,882,000-128,191,000-61,720,000-47,404,000-181,343,000-112,465,000-67,033,000-60,341,000-41,015,000-71,537,000
EBT Margin6.2%-0.70-0.74-0.91-0.84-0.78-0.84-0.77-0.88-0.90-0.96-0.90-0.75---------
Net Income41.2%-91,576,000-155,792,000-132,970,000-198,883,000-138,959,000-170,889,000-109,315,000-152,087,000-126,726,000-143,265,000-133,624,000-118,370,000-128,642,000-74,354,000-69,692,000-181,427,000-112,687,000-77,677,000-59,997,000-41,789,000-72,113,000
Net Income Margin6.5%-0.62-0.67-0.80-0.75-0.74-0.80-0.76-0.90-0.92-0.97-0.92-0.83---------
Free Cashflow157.8%61,173,000-105,854,000-20,876,000-20,365,000-39,761,000-174,585,000-43,427,000-63,942,000-106,716,000-77,566,000-57,034,000-39,119,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-5.6%1,7901,8961,2601,3381,6091,7061,5761,8041,8001,9382,0072,0592,1122,2082,1811,4771,5461,6241,6411,2921,284
  Current Assets-4.1%1,1691,2195405906136945176957749541,0111,0661,1221,2321,244605692779807475479
    Cash Equivalents-7.7%548594165208234296121174152197197185154216441166131296531136201
  Inventory-1.7%30.0031.0036.0032.0027.0022.0015.0015.0015.0016.0016.0016.0016.0019.0019.0018.0019.0019.0017.0017.0016.00
  Net PPE6.5%93.0087.0085.0082.0079.0073.0067.0065.0059.0053.0046.0043.0037.0034.0028.0027.0026.0022.0018.0015.0015.00
  Goodwill0.0%82.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.0082.00
Liabilities-1.1%2,6842,7141,9311,9172,0662,0531,8031,9861,8901,9371,9021,8621,8191,7261,6709041,0171,029978803771
  Current Liabilities-4.7%575603492476442406420567477509465291251277254202218236184174143
  Long Term Debt0.1%285284573573572572283282282282282430430309303297295294293136138
    LT Debt, Current--------150150150149--8.00-18.0020.0020.0020.0020.0017.00
    LT Debt, Non Current0.1%285284573573572572283282282282282430430309303297295294293136138
Shareholder's Equity-9.2%-893-818---457-347---1.00105197293482511572529594664489513
  Retained Earnings-2.8%-3,375-3,283-3,127-2,994-2,795-2,656-2,486-2,376-2,224-2,097-1,954-1,821-1,702-1,628-1,554-1,484-1,303-1,190-1,112-1,052-1,011
  Additional Paid-In Capital0.8%2,4872,4662,4472,4172,3402,3052,2232,1842,1532,1242,0932,0642,034-1232,1012,0671,8341,7951,7761,5401,523
Shares Outstanding1.2%77.0076.0075.0075.0074.0073.0071.0071.0071.0070.0071.0070.00---------
Float----2,331---2,130---2,191---2,923---2,567-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations170.6%71.00-100-14.52-14.12-29.49-165-38.04-55.24-97.40-68.84-51.19-31.14-100-64.3727.00-74.81-81.55-10.21-15.50-30.52-42.41
  Share Based Compensation11.3%18.0017.0027.0029.0029.0027.0029.0028.0027.0026.0026.0026.0026.0021.0017.0017.0015.0011.0010.0011.009.00
Cashflow From Investing-21.7%-114-94.42-29.60-23.75-28.9732.0013672.0049.0068.0065.0056.0030.00-208-394142-101-22930.00-38.17-150
Cashflow From Financing-99.9%1.006203.0018.004.00303-1394.001.004.003.004.0010.0040.00643-32.9218.002.003823.00226
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PTCT Income Statement

2024-03-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenue$ 210,118$ 220,382
Operating expenses:  
Cost of product sales, excluding amortization of acquired intangible assets14,74014,144
Amortization of intangible assets51,53039,415
Research and development116,129195,124
Selling, general and administrative73,27286,914
Change in the fair value of contingent consideration(100)2,400
Total operating expenses255,571337,997
Loss from operations(45,453)(117,615)
Interest expense, net(40,834)(27,331)
Other income, net1,5919,956
Loss before income tax expense(84,696)(134,990)
Income tax expense(6,880)(3,969)
Net loss attributable to common stockholders$ (91,576)$ (138,959)
Weighted-average shares outstanding:  
Basic76,496,12773,729,284
Diluted76,496,12773,729,284
Net loss per share-basic and diluted (in dollars per share)  
Basic$ (1.20)$ (1.88)
Diluted$ (1.20)$ (1.88)
Net product revenue  
Revenues:  
Revenue$ 177,604$ 187,557
Collaboration revenue  
Revenues:  
Revenue 6
Royalty revenue  
Revenues:  
Revenue31,15430,831
Manufacturing revenue  
Revenues:  
Revenue$ 1,360$ 1,988

PTCT Balance Sheet

2024-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 548,355$ 594,001
Marketable securities336,458282,738
Trade and royalty receivables, net197,660160,822
Inventory, net30,05830,577
Prepaid expenses and other current assets56,207150,491
Total current assets1,168,7381,218,629
Fixed assets, net92,77987,089
Intangible assets, net330,040379,497
Goodwill82,34182,341
Operating lease ROU assets91,18691,896
Deposits and other assets24,54536,246
Total assets1,789,6291,895,698
Current liabilities:  
Accounts payable and accrued expenses330,924391,983
Deferred revenue 801
Operating lease liabilities- current14,57213,002
Finance lease liabilities- current1,9483,000
Liability for sale of future royalties - current227,102194,314
Total current liabilities574,546603,100
Long-term debt284,512284,213
Contingent consideration payable36,20036,300
Deferred tax liability55,90455,905
Operating lease liabilities- noncurrent104,83797,627
Finance lease liabilities- noncurrent15,57417,184
Liability for sale of future royalties- noncurrent1,611,8311,619,783
Other long-term liabilities141141
Total liabilities2,683,5452,714,253
Stockholders' deficit:  
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,653,960 shares at March 31, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 20237675
Additional paid-in capital2,486,7222,466,233
Accumulated other comprehensive loss(5,560)(1,285)
Accumulated deficit(3,375,154)(3,283,578)
Total stockholders' deficit(893,916)(818,555)
Total liabilities and stockholders' deficit$ 1,789,629$ 1,895,698
PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
 CEO
 WEBSITEptcbio.com
 INDUSTRYBiotechnology
 EMPLOYEES1402

PTC Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for PTC Therapeutics Inc? What does PTCT stand for in stocks?

PTCT is the stock ticker symbol of PTC Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PTC Therapeutics Inc (PTCT)?

As of Fri May 17 2024, market cap of PTC Therapeutics Inc is 2.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers. The fair value of PTC Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PTC Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PTC Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTCT is over valued or under valued. Whether PTC Therapeutics Inc is cheap or expensive depends on the assumptions which impact PTC Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTCT.

What is PTC Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PTCT's PE ratio (Price to Earnings) is -4.38 and Price to Sales (PS) ratio is 2.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on PTC Therapeutics Inc's stock?

In the past 10 years, PTC Therapeutics Inc has provided 0.083 (multiply by 100 for percentage) rate of return.